On what the healthcare system asks patients to do, what it assumes they have, and what it might look like if repair were actually accessible.
How Clinical "Compliance" Assumes Privilege Most Patients Don't Have
What We Actually Talk About When We Talk About Compliance
In medical literature, "compliance" means the extent to which a patient's behavior matches the prescriber's recommendations. Sounds neutral.
...It isn't.
The term itself reveals the power dynamic. Compliance implies obedience to authority; the patient following doctor's orders without question. That's why the field shifted to "adherence" in the early 2000s, acknowledging that patients and clinicians should collaborate rather than one commanding and the other obeying.
But even "adherence" keeps the focus on whether patients follow treatment protocols. It doesn't ask whether those protocols are followable given patients' actual circumstances. The Royal Pharmaceutical Society pushed for "concordance": agreement and harmony between patient and clinician about treatment goals, recognizing that what looks like non-adherence is often an informed decision based on constraints the medical system doesn't account for.
Here's what's measured: Medication Possession Ratio (MPR) and Proportion of Days Covered (PDC). These calculate what percentage of days a patient has medication available based on pharmacy refill records. The standard threshold is 80%; if you have medication available less than 80% of the time, you're documented as "non-adherent."
That 80% cutoff determines insurance reimbursement, provider performance metrics, and whether patients get blamed when treatment fails.
What it doesn't measure: whether having the medication means you can actually take it.
What Compliance Actually Costs
Take MS treatment. At the time of drafting this, my game plan is Rituximab infusions every six months. The protocol documentation shows: medication name, dose, frequency.
Clean. Simple.
What it doesn't show: infusion centers open weekdays 8am-5pm. Four to six hours per infusion. Transportation required both ways (can't drive after due to reaction risk). Prior authorization from insurance every time. Copays ranging from $50 to $5000 depending on your plan. Time off work; unpaid if you're hourly.
Add the baseline requirements protocols assume exist: stable housing with refrigeration for medications requiring cold storage. Reliable transportation or $40 each way for medical transport. English fluency to navigate insurance bureaucracy. Phone and internet access to schedule appointments and receive test results. Income buffer so medical copays don't mean choosing between medication and rent.
Most protocols assume all of this. Most patients don't have all of this.
What the Research Actually Studies
Clinical trials for MS medications typically exclude: anyone without stable housing; anyone without health insurance; anyone who can't commit to frequent monitoring appointments; anyone who can't read and sign consent forms in English; anyone with "barriers to treatment adherence."
Then the treatment protocols developed from these trials get applied to everyone. And when patients can't follow protocols designed for people with resources they don't have, it gets documented as "non-compliant."
The research population is not representative. But the compliance standards are universal.
A 2018 study of MS patients found high out-of-pocket costs for disease-modifying therapies correlated with lower adherence and inappropriate disease management, leaving patients at increased risk of relapse. About 25% of MS patients receive medications at little or no cost through pharmaceutical assistance programs, but federal regulations prevent patients with government insurance (Medicare, Medicaid) from using these programs.
The access bind: patients most likely to need financial assistance are specifically barred from receiving it.
French researchers found patients from less socioeconomically deprived areas had 2.13 times higher likelihood of accessing second-line MS treatment compared to more deprived patients; even when both groups had equivalent disease severity and treatment need. Geographic isolation compounded the effect: patients in rural areas often chose not to pursue MS care because travel times made it functionally impossible.
A Medicare study tracking MS patients nationally found medication adherence dropped significantly between December and January each year: from 76% to 65%.
That's not patients suddenly forgetting to take medication. That's patients hitting annual deductible resets and making impossible choices about whether they can afford to continue treatment.
The Compliance Framework Breaks Both Ways
Non-compliance isn't just documented: it's penalized. Insurance reimbursement rates favor "adherent" patients. Provider performance metrics track patient adherence as a measure of care quality. When outcomes are poor, non-adherence becomes the explanation.
But "non-adherent" often means: couldn't afford the copay. Lost job due to disability. Couldn't get time off work. No transportation to appointments. Insurance denied prior authorization. Pharmacy 40 miles away with no car. Treatment requires cognitive capacity that the disease itself impairs.
None of that appears in the medical record as systems failure. It appears as patient failure.
The cognitive bind deserves particular attention: MS impairs executive function. Depression impairs decision-making capacity. ADHD affects medication routine maintenance. Post-traumatic stress interferes with healthcare engagement. The conditions requiring the most complex treatment protocols are often the ones that make managing those protocols hardest.
Treatment protocols don't account for this. If you can't manage the administrative burden of your own care: coordinating specialists, tracking appointments, fighting insurance denials, refilling prescriptions before running out, monitoring symptoms: it gets documented as non-compliance. Not as "disease affects patient's ability to coordinate care." Just: non-compliant.
The system requires compliance it doesn't enable.
Fixing this requires: research that includes patients without ideal circumstances; treatment protocols that account for real barriers; healthcare economics that don't punish providers when patients can't afford care; care coordination that's actually funded and functional; and acknowledging "non-compliance" as systems failure, not patient character flaw.
Until those things change, we'll keep seeing marginalized patients get blamed when treatment fails. The disease progression that follows isn't moral failing. It's predictable outcome when systems demand resources patients don't have and then penalize patients for that lack.
The compliance framework measures whether patients follow protocols. It doesn't measure whether protocols are followable. That gap, between what clinical standards demand and what material reality permits, is where patients fall through.
November 7th 2025: I came home from work yesterday unable to stop crying after I ran into a neighbor who looked familiar, like a pre-2020 close friend. My work day was acutely stressful (I help vulnerable populations try to survive in NYC at this contract) and I had the kind of complete emotional disintegration I've experienced since I was a teenager: where the stress reaches a threshold and my nervous system just... gives up on regulation entirely.
So today I stayed home. Medical scheduling circus shit yesterday and today stressed me out enough that my legs felt like clay; the brainfog and stinging eyes made the idea of getting on the train laughable.
For over a decade, I've understood these as autistic meltdowns. In 2013/2014, my PhD psychologist and my psychiatrist agreed I likely have high-functioning autism spectrum disorder. My learning disability testing showed processing speeds that corroborated that theory. My psychiatrist changed my bipolar diagnosis to "rule out" because my mood problems didn't match bipolar patterns (they were stress-reactive, not cyclical). The meltdowns tracked with sensory overload and executive function collapse, not mood episodes.
Getting that autism framework was a relief. Finally, an explanation that fit. I've been proud of that diagnosis. It explained decades of feeling like I was doing life wrong, like everyone else got a manual I didn't receive.
But now I have MS. Diagnosed at 42, symptoms since 14. Same timeframe as when these meltdowns started.
And I need to be really careful here because I'm trying to explain to my neurologist that not everything in my life can be explained by multiple sclerosis. I have a complicated life full of contraindications. Autism is real. Generalized anxiety disorder is real. I pursued treatment for PTSD in my twenties after being raised by an abusive parent, and I've managed that proactively with therapy and pharmaceuticals ever since.
Basically: always trying to give myself a higher quality of life after growing up with a very reduced one. MS doesn't erase those diagnoses or replace them.
But also: stress-induced MS symptom exacerbation is also real. And I need the neurologists involved in my future to take this seriously.
The Experiment I Didn't Mean to Run
Once upon a time, I was in a toxic workplace. I'd been hired into a position with project management expectations I couldn't ethically meet. Six months in, rather than just firing me, they put me on a performance review that had nothing to do with what I'd actually been hired to do or had been doing. It was baffling but it was also foul.
It was delivered with the icy passive-aggressive Midwestern niceness that tells people like me that we're in mortal danger.
I melted down. I quit.
And then something terrifying happened bit by bit: I could walk easily again.
Still wobbly. Still had right foot drop. But I could walk. The dramatic worsening that had appeared earlier in the year; legs so weak I was falling out of bed in the morning; it improved rapidly after I left that job.
The psychological stressor was directly feeding into my physical disability symptoms.
That was clarifying in the worst possible way. Because it meant that for months, I'd been experiencing MS symptom exacerbation triggered by workplace stress, and I hadn't been able to name it as such because I didn't have the diagnosis yet.
What the Past 72 Hours Looked Like
I've known for two years that stress makes me stiffer, but this month it is worse. I fall over when I have too much stress. (Pour one out for my downstairs neighbors; it's been a long almost two years for them hearing me hit the floor at least once a day.)
Cognitively and physically I cannot stop crying even when I take my hydroxyzine.
So I sent my neurologist a panicked MyChart message. And then another one. (Pour one out for my neurologist's team; I type so fast and can tightly pack MyChart character limits with research links.)
That's where I am.
What the Research Actually Says
After yesterday's meltdown, I went looking for studies on stress, MS, and emotional regulation. Here's what I found:
Stress Reliably Triggers MS Exacerbations
Multiple studies show that emotional stress (sustained or intense, not just daily hassles) is associated with MS exacerbations:
This is NOT pseudobulbar affect (that's when you laugh or cry inappropriately without matching your actual emotions). What I'm experiencing: cannot stop crying when actually stressed and upset: is different. This is stress-induced symptom exacerbation affecting both emotional regulation and motor function.
Autism and Emotional Regulation Are Also Real
Emotion regulation: Concepts & practice in autism spectrum disorder: impaired emotion regulation may be intrinsic to ASD; uncontrolled outbursts often stem from ineffective management of emotional states in response to stress or overstimulation. Not defiance. Not weakness.
Multiple Sclerosis and Autism: Overlapping symptoms: when autism and MS coexist, overlapping symptoms complicate the clinical picture; sensory processing issues, motor difficulties, cognitive challenges, fatigue, and emotional regulation difficulties
What This Means
I've been correctly treating these as autistic meltdowns for over a decade. My emotional dysregulation is real and autism-related.
But now that I know I've had MS since age 14 (same timeframe as when these meltdowns began), it's clear that: MS-related stress sensitivity is making my autistic emotional regulation challenges worse; stress triggers both autism-related meltdowns AND MS symptom exacerbation including motor symptoms like altered gait and foot drop; and the two conditions compound each other: autism makes stress harder to regulate, stress triggers MS symptoms, MS symptoms create more stress.
The historical workplace situation proved this. Remove the major stressor: motor symptoms improve. That's not psychosomatic. That's documented stress-induced MS exacerbation.
The Balancing Act
Here's what I need my neurologist to understand: I'm not trying to make MS the silver bullet explanation for my entire complicated life. I'm not suddenly attributing everything to demyelination.
I have autism. I have Generalized Anxiety Disorder. I addressed a PTSD diagnosis in my twenties through therapy, and I've managed it proactively ever since. I've spent my adult life being proactive about my mental health and quality of life, using both therapy and pharmaceuticals, because I grew up with a very reduced quality of life due to an abusive parent and I've always worked to do better for myself.
But my material conditions and ideals rarely aligned. Mental health and behavioral health was my proximate priority due to it being much more accessible for DIY treatments when times got tough. Physical health? Oh. That. I have a 28-year diagnostic delay that involved repeated medical dismissal and economic barriers to care. I have trauma around not being believed about my body. All of those things are real and shaped who I am.
And also I have MS that started in adolescence and has been affecting my nervous system's stress response for 28 years.
This is not reductive. This is adding complexity, not removing it.
The question I'm sitting with: how much of what I've been managing as "just autism" or "just anxiety" might actually be autism and anxiety and MS interacting in ways I couldn't name until now?
When I quit that toxic job and could suddenly walk better, that wasn't my autism improving or some critical self-care win. That was MS symptom exacerbation resolving. Which means for months in 2024, I was experiencing disease activity accelerated by workplace stress. (Which hole in my brain MRI should I name after that startup?)
Why This Matters for Treatment
If stress reliably triggers MS symptom exacerbation (including motor symptoms like the foot drop and altered gait I developed in spring 2024) then this isn't just about mental health management. This is disease-modifying behavior we're talking about.
Stress management isn't just "good self-care" for me; it's literally MS treatment.
Unfortunately as an uninsured pauper, I get 15-minute windows to present my complex psychosocial history and recent clearly-MS flares to my neurologist; and his team ends up missing critical information about my disease pattern and what triggers my relapses.
I'm not trying to over-medicalize my life. I'm trying to get my medical team to see the whole picture: multiple neurological conditions, multiple diagnoses, complex interactions, and a long history of proactive mental health management. Not simple. Not reducible to one thing.
The Contraindication
My life is full of contraindications. That's the whole point of this writing. I'm contraindicated and the system wasn't designed for people like me.
But that doesn't mean the MS isn't real, or that it isn't making things worse in ways I'm only now beginning to understand.
It means that I will simply (lmao) need a neurologist who can hold multiple truths at once: autism is real and affects my stress response; historical PTSD that I've managed proactively for years is real and affects my nervous system; MS is real and stress makes it worse; and all three interact in ways that make me more vulnerable to symptom exacerbation under sustained stress.
The 2024 workplace situation was an unintended controlled experiment. Major stressor introduced: motor symptoms worsen. Major stressor removed: motor symptoms improve.
That's not "all in my head." That's documented, reproducible, stress-induced MS exacerbation.
And if my medical team can't see that pattern, then they're missing critical information about my disease management needs.
Take care of yourselves. Complexity isn't weakness. And if stress makes your symptoms worse, that's not weakness either; that's your nervous system telling you something important.
Maybe+Future: When Repair Becomes Possible (But Not Necessarily Accessible)
What Is Remyelination?
Your nervous system sends signals along nerve fibers called axons. These axons are wrapped in myelin: a fatty insulation that speeds up signal transmission and provides metabolic support to keep neurons healthy. In multiple sclerosis and other demyelinating conditions, the immune system attacks this myelin coating. Signals slow down or stop. Neurons become vulnerable to damage.
Remyelination is the process of repairing that insulation. Your brain can do this naturally, to some extent. Cells called oligodendrocytes can wrap new myelin around damaged axons, restoring faster conduction and protecting neurons from degeneration. The question researchers are asking: can we enhance this repair process with drugs or other interventions?
The answer, increasingly, is maybe. That's genuinely exciting!
The Good News
A 2020 review in The Lancet Neurology summarized decades of remyelination research and emerging clinical trials. PET imaging studies can now track myelin repair in living patients over time. Some people naturally repair better than others: "good remyelinators" versus "bad remyelinators." Patients with better remyelination profiles showed less brain atrophy and preserved neurological function compared to those with poor repair.
Clinical trials are testing compounds that might enhance repair: clemastine (an over-the-counter antihistamine), electrical stimulation, monoclonal antibodies, drugs repurposed from other conditions. Early results show small improvements in nerve conduction. Evidence suggests that even decades-old oligodendrocytes might still be capable of wrapping new myelin around damaged axons. Repair might be possible even in long-established disease.
This is real progress. The kind that offers hope for slowing disability progression rather than just managing acute flares.
The Unicorn Patient
But here's the structural problem nobody's talking about in public: the ideal candidate for these trials barely exists in current material conditions.
Most remyelination trials recruit patients with: acute optic neuritis (recent, single episode of vision loss); early relapsing-remitting MS (diagnosed within past few years); stable disease on highly effective immunotherapy; access to specialized research centers with PET imaging capabilities; ability to attend multiple appointments for scans, nerve conduction testing, MRI sequences; and insurance that covers experimental protocols or financial resources to self-pay.
That's not most people with demyelinating disease.
The median diagnostic delay for MS is 1-5 years depending on population and symptom presentation. For people whose symptoms don't match textbook patterns (women with "atypical" presentations, Black and Latinx patients, people with complex medical histories) delays stretch longer. By the time someone gets diagnosed, they've often accumulated years of demyelination. They're not "early" disease anymore.
The acute optic neuritis trials require catching people within weeks of symptom onset. That assumes prompt access to specialty care, immediate MRI availability, and physicians who recognize optic neuritis as a demyelinating event rather than attributing vision changes to other causes.
The trials testing remyelination in established MS require patients who are stable on disease-modifying therapy. But getting stable requires privileges: insurance that covers high-efficacy DMTs, no insurance gaps during job transitions, the ability to tolerate side effects without losing work, access to specialists who prescribe newer medications rather than keeping patients on older, less effective drugs due to insurance step therapy requirements.
The PET imaging study that identified "good remyelinators" versus "bad remyelinators" is fascinating science. It suggests some people's brains naturally repair better than others. But we don't know yet which treatments work for which remyelination profiles. We don't have biomarkers to predict who will respond. The heterogeneity between patients means trial results show small average improvements that might mask dramatic responses in subgroups we can't yet identify.
The Access Gap
Even if these therapies prove effective, how long until they're accessible?
Clemastine is over-the-counter. That's promising. But the ReBUILD trial used specific dosing protocols under medical supervision with regular monitoring for a crossover study in chronic optic neuritis. The results showed reduced latency in visual evoked potentials (evidence of remyelination) but only in the per-protocol population, not intention-to-treat analysis. Will insurance cover that monitoring? Will primary care doctors prescribe it off-label? Will patients in countries without robust healthcare systems have access to the follow-up testing required to know if it's working?
The more sophisticated interventions (monoclonal antibodies like opicinumab, electrical stimulation devices, drugs requiring PET scan monitoring to assess response) will be expensive. They'll require specialist care. Patients will need the time and resources to attend appointments. The ability to take time off work. Reliable transportation. Stable housing.
The same structural barriers that cause diagnostic delays will determine who gets access to repair therapies.
Still Worth It
None of this means the research isn't worth doing. It absolutely is. Understanding remyelination mechanisms might eventually lead to more accessible interventions. Identifying which patients respond to which treatments could reduce the trial-and-error period. Proving that repair is possible shifts the entire paradigm from "manage decline" to "promote recovery."
But we need to be honest about the gap between "repair becomes possible" and "repair becomes accessible." The ideal trial candidate is a unicorn. Research that only serves unicorns isn't serving most patients.
The question isn't just whether remyelination therapy works. It's whether it works for people who don't fit the inclusion criteria. Whether anyone will be able to access it when their diagnostic delay, insurance status, and material conditions made them ineligible for the trials that proved efficacy in the first place.
